Clinical trial · Interventional
The Safety and Efficacy Evaluation of XSLJZ in Advanced Hepatocellular Carcinoma Patients With Multiple Protein Kinase Inhibitor Therapy: A Randomized, Double-Blind, Controlled Trial
NCT04562428CI-TRIAL-00077197completedPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the study was search the safety and efficacy of the of Xiang Sha Liu Jun Zi Decoction (XSLJZ) in advanced hepatocellular carcinoma patients with multiple protein kinase inhibitor therapy. Evaluate the treatment effect on the symptoms of appetite and quality of life in advanced hepatocellular carcinoma patients
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Xiang Sha Liu Jun Zi Decoction dry powder | Drug | — | UNRESOLVED |
| XSLJZ Placebo | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- XSLJZ
- description
- Xiang Sha Liu Jun Zi Decoction dry powder 7.5g/day tid
- interventionNames
- Drug: Xiang Sha Liu Jun Zi Decoction dry powder
- type
- PLACEBO_COMPARATOR
- label
- XSLJZ Placebo
- description
- 10%Xiang Sha Liu Jun Zi Decoction dry powder 7.5g/day tid
- interventionNames
- Drug: XSLJZ Placebo
Primary outcomes (5)
- measure
- body weight
- timeFrame
- 8 weeks
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Advanced hepatocellular carcinoma patient 2. use multiple protein kinase inhibitor therapy paid by National Health Care Insurance system (NHCIS) in Taiwan 3. Child-Pugh A class 4. Eastern Cooperative Oncology Group performance status of 0-2 5. survival period over 3 months 6. used Xiang Sha Liu Jun Zi Decoction for one month before the multiple protein kinase inhibitor therapystarting point Exclusion Criteria: 1. combine other cancer at the same time 2. ESRD under dialysis 3. heart disease,CHF、CAD、arrhythmia、hypertension (SBP\>150mmHg，DSP\>90 mmHg) 4. current serious infection 5. GI bleeding within 30 days 6. receive organ transplant 7. Child-Pugh Class B or C liver status。 8. Refractory Ascites in Liver Cirrhosis
References
Publications (0)
Data not yet available
No reference posted for this study.